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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to olive 
(Olea europaea L.) leaf water extract and increase in glucose tolerance 
pursuant to Article 13(5) of Regulation (EC) No 1924/20061 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)2,3 
European Food Safety Authority (EFSA), Parma, Italy 
This scientific output, published on 23 July 2014, replaces the earlier version published on 5 May 2014*  
ABSTRACT 
Following an application from Comvita New Zealand Limited, submitted pursuant to Article 13(5) of Regulation 
(EC) No 1924/2006 via the Competent Authority of the United Kingdom, the Panel on Dietetic Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to olive (Olea europaea L.) leaf water extract and increase in glucose tolerance. The food that is the 
subject of the health claim, olive leaf water extract standardised by its content of oleuropein, is sufficiently 
characterised. The claimed effect, an increase in glucose tolerance, is a beneficial physiological effect as long as 
serum insulin concentrations are not disproportionately increased. One human intervention study showed an 
increase in glucose tolerance without disproportionate increase in insulin concentrations after daily consumption 
of the olive leaf water extract for 12 weeks under the conditions of use proposed by the applicant. However, the 
results have not been replicated in other studies, and no evidence has been provided in relation to the mechanism 
by which the olive leaf water extract could exert the claimed effect. The scientific evidence is insufficient to 
establish a cause and effect relationship between the consumption of olive leaf water extract and an increase in 
glucose tolerance. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Comvita New Zealand Limited, submitted pursuant to Article 13(5) of 
Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific 
substantiation of a health claim related to olive leaf water extract and increase in glucose tolerance. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application includes a request for the protection of proprietary data. 
The food that is the subject of the health claim is olive (Olea europaea L.) leaf water extract 
standardised by its content of oleuropein. The Panel considers that the food, an olive leaf water extract 
(standardised by its content of oleuropein), which is the subject of the health claim, is sufficiently 
characterised. 
The claimed effect proposed by the applicant refers to “reduces the glycaemic response following 
carbohydrate consumption”. The target population is adults willing to reduce their glycaemic response. 
Upon request by EFSA for clarification, the applicant indicated that the claimed effect relates to a 
long-term increase in glucose tolerance, which could be assessed in vivo in humans by an oral glucose 
tolerance test (OGTT) following chronic consumption (e.g. 12 weeks) of the food that is the subject of 
the health claim. The Panel considers that an increase in glucose tolerance is a beneficial physiological 
effect as long as serum insulin concentrations are not disproportionately increased. 
The applicant identified two human studies and three animal studies as being pertinent to the claim. 
The Panel considers that no conclusion could be drawn from one human study and from the three 
animal studies as they were conducted with foods which do not comply with the specifications 
provided by the applicant in relation to the food that is the subject of the health claim. The Panel 
considers that the other human study shows an increase in glucose tolerance without disproportionate 
increase in insulin concentrations after consuming the water extract of fresh olive leaves daily for 12 
weeks under the conditions of use proposed by the applicant. 
The applicant proposed three mechanisms by which olive leaf water extract could exert the claimed 
effect: (1) through an acute increase in interleukin 6 (IL-6) in skeletal muscle after exercise, which 
could improve insulin-regulated glucose metabolism in the muscle; (2) through decreased 
carbohydrate absorption by inhibiting α-glucosidase in the gut, salivary or intestinal α-amylase 
activity, or stimulating hepatic glycogen synthesis; and (3) through increasing the activity of hepatic 
antioxidant enzymes. The Panel considers that the information supplied by the applicant did not 
provide evidence for the mechanism by which the olive leaf water extract could exert the claimed 
effect. 
On the basis of the data presented, the Panel concludes that the scientific evidence is insufficient to 
establish a cause and effect relationship between the consumption of olive leaf water extract and an 
increase in glucose tolerance. 
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BACKGROUND 
Regulation (EC) No 1924/20064 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the Community 
list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
• The application was received on 25/09/2013. 
• The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. 
• The scientific evaluation procedure started on 25/10/2013. 
• On 22/01/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the clock 
was stopped on 29/01/2013, in compliance with Art. 18(3) of Regulation (EC) No 1924/2006. 
• On 13/02/2014, EFSA received the requested information as submitted by the applicant and 
the clock was restarted. 
• During its meeting on 10/04/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to olive leaf water 
extract and increase in glucose tolerance. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to olive leaf water extract and increase in 
glucose tolerance. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of olive leaf water extract, a positive assessment of its safety, nor a decision on whether olive leaf 
water extract is, or is not, classified as a foodstuff. It should be noted that such an assessment is not 
foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Comvita New Zealand Limited, 23 Wilson Road South, Paengaroa, 
Bay of Plenty, 3189, New Zealand. 
The application includes a request for the protection of proprietary data for bioavailability data and 
one unpublished study (Lockyer, 2012) in accordance with Article 21 of Regulation (EC) 
No 1924/2006. 
Food as stated by the applicant 
According to the applicant, the food is “polyphenol-rich water extract of fresh olive leaf (Olea 
europaea L.)”. The extract consists of a complex mixture of polyphenols and is standardised by its 
content of oleuropein (at least 50 mg per daily intake). The composition of olive leaf extract varies, 
but in all olive leaf extract products oleuropein is the principal component, normally contributing 20–
40 % of the total phenolics present. 
Health relationship as claimed by the applicant 
According to the applicant, “regular (daily) consumption of polyphenol-rich water extract of fresh 
olive leaf reduces the glycaemic response following carbohydrate consumption”. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wordings for the health claim: “daily intake of supplemental 
olive leaf extract polyphenols contributes to the reduction of the blood glucose rise after meals”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed a daily intake of five Comvita OLE capsules, each containing 400 mg 
OLE (olive leaf extract) as 6:1 concentrate, equivalent to 2.4 g fresh leaf, with a daily intake providing 
at least 50 mg oleuropein. The target population is adults willing to reduce their post-prandial 
glycaemic response. It will be particularly beneficial to individuals with impaired glucose tolerance, a 
common condition in the general adult population, particularly among those who are overweight or 
obese. 
ASSESSMENT 
1. Characterisation of the food 
The food that is the subject of the health claim is “polyphenol-rich water extract of fresh olive leaf 
(Olea europaea L.)”, OLE. The product is a soft gel capsule containing 400 mg OLE as 6:1 
concentrate, equivalent to 2.4 g fresh leaf. The food is standardised by its content of oleuropein. 
The Panel notes that the major phenolic constituents in olive leaves are the glycosylated forms of 
oleuropein (Visioli et al., 2002; Vissers et al., 2002; de Castro and Capote, 2010). Oleuropein is the 
elenolic acid ester of hydroxytyrosol, representing 1–14 % of olive leaf weight. The composition of 
commercial olive leaf extracts varies, with oleuropein normally contributing 20–40 % of the total 
phenolic compounds (Benavente-Garcia, 2000; Lockyer et al., 2012). Depending on the olive tree 
variety, the harvesting season, the stage of leaf maturity, the storage conditions and the extraction 
method used, the content of oleuropein may vary greatly in the olive leaf extracts. 
Upon request by EFSA, the applicant confirmed that the amount of oleuropein in one capsule of 2.4 g 
olive leaf water extract is 9.5–16.7 mg (batch-to-batch analysis). In addition, the applicant stated that, 
owing to a recent change in the leaf harvesting technique, the oleuropein content in the capsules had 
increased to an average of 24.1 mg/capsule (five batches analysed). 
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The oleuropein content in the capsules was measured using established methods. The applicant 
provided information about stability of the product over 24 months. Olive leave polyphenols are 
absorbed, as polyphenol metabolites were measured in plasma and urine after oral consumption. 
The Panel considers that the food, an olive (Olea europaea L.) leaf water extract standardised by its 
content of oleuropein, which is the subject of the health claim is sufficiently characterised 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant refers to “reduces the glycaemic response following 
carbohydrate consumption”. The target population is adults willing to reduce their glycaemic response. 
Upon  request by EFSA for clarification, the applicant indicated that the claimed effect relates to a 
long-term increase in glucose tolerance, which could be assessed in humans by an oral glucose 
tolerance test (OGTT) following chronic consumption (e.g. 12 weeks) of the food that is the subject of 
the health claim. 
The Panel notes that a long-term increase in glucose tolerance is a beneficial physiological effect as 
long as serum insulin concentrations are not disproportionately increased. The scientific evidence for 
the substantiation of health claims related to an increase in glucose tolerance can be obtained from 
human intervention studies showing a decrease in blood glucose concentrations at different time points 
during a standard (WHO, 1999) OGTT and with no disproportionate increase in insulin concentrations 
following chronic consumption (at least 12 weeks) of the food that is the subject of the health claim. 
The Panel considers that an increase in glucose tolerance is a beneficial physiological effect as long as 
serum insulin concentrations are not disproportionately increased. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in Medline, Embase, Embase Alert and Cochrane Library 
databases using the following key terms: olive leaf extract, Olea europaea, oleuropein, glucose and 
insulin, with a time period from 1980 to present, published in English. A manual search of review 
articles was also performed. Exclusion and inclusion criteria applied to select the pertinent 
publications were reported. 
The applicant identified two human studies (Komaki et al., 2003; de Bock et al., 2013), and three 
animal studies (Komaki et al., 2003; Poudyal et al., 2010; Wainstein et al., 2012) as being pertinent. 
In a randomised, double-blind, placebo-controlled, crossover, two-arm human intervention study (de 
Bock et al., 2013), 46 overweight male volunteers (mean age 46.4 ± 5.5 years, body mass index (BMI) 
28.0 ± 2.0) consumed once a day four capsules of olive leaf water extract suspended in safflower oil 
(containing 51.1 mg oleuropein) or four capsules containing placebo (safflower oil only) for 12 weeks, 
crossing over to the other intervention after a six-week washout. The exclusion criteria were tobacco 
use, diabetes or being on medications likely to affect insulin sensitivity. Subjects taking 
antihypertensive or lipid-lowering medications were recruited, but were required to have been on a 
stable dose for at least six months prior to the start of the study. At the beginning of the study and at 
the end of each intervention phase, glucose and insulin concentrations were measured in blood 
samples taken at baseline and at 30-minute intervals for 2 hours during a standard OGTT with 75 g of 
glucose; body composition was assessed by dual-energy X-ray absorptiometry (DXA); physical 
activity levels were scored using the International Physical Activity Questionnaire (IPAQ), which 
covers four domains of physical activity: work-related, transportation, housework/gardening and 
leisure time. Three-day dietary records were collected at baseline and at clinical assessment following 
each 12-week intervention. Fasting blood lipids, insulin-like growth factor I (IGF-I), IGF-II, IGF-
binding protein 1 (IGFBP-1), IGFBP-2, IGFBP-3, ultra-sensitive C-reactive protein (CRP), tumour 
necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), interleukin 8 (IL-8), as well as 24-hour 
Olive leaf water extract and increase in glucose tolerance 
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ambulatory blood pressure and the carotid intima–media thickness, were also measured at the 
beginning of the study and at the end of each intervention phase. 
Sample size was calculated for the primary outcome of the study, the surrogate index of whole-body 
insulin sensitivity, ISI(composite), which is calculated considering fasting plasma glucose and insulin 
concentrations, as well as mean plasma glucose and insulin concentrations during the standard OGTT 
as described by Matsuda and DeFronzo (1999). Considering a mean adult ISI(composite) of 15.6 and a 
standard deviation (SD) of 8.7, it was calculated that 46 subjects would be needed to detect a 25 % 
difference between the intervention and placebo with 80 % power at a 0.05 significance level. 
Secondary outcomes included the areas under the curve (AUC) for glucose and insulin during the 
OGTT, circulating cytokines, lipid profile, body composition, 24-hour ambulatory blood pressure and 
carotid intima–media thickness. Linear mixed models were used to assess the main treatment effect 
accounting for randomisation sequences and time periods, while adjusting for baseline values of the 
outcome being assessed. On-going use of medication (for cholesterol or hypertension), IPAQ scores, 
age and per cent body fat were also added as covariates in the analyses. 
Three subjects dropped out while taking placebo, one during period 1 (because of injury) and two after 
crossing over (one was lost to follow-up and one because of development of acne). Statistical analyses 
were performed in 45 participants. Compliance with the study products was > 96 %. The ISI(composite) 
was significantly higher after consumption of the olive leaf water extract than after consumption of 
placebo (+15 %, 5.46 vs. 4.73; p = 0.024). The Panel notes that this between-groups difference was 
lower than the 25 % considered meaningful for power calculations. The AUC for both glucose and 
insulin were significantly lower following consumption of the olive leaf water extract than following 
consumption of placebo (–6 % (p = 0.008) and –14 % (p = 0.041), respectively), which was consistent 
with significantly lower glucose concentrations at 30 minutes (–6 %; p = 0.008) and 60 minutes (–
10 %; p = 0.005), and with lower insulin concentrations at 60 minutes (–23 %; p = 0.004). There were 
no significant changes in any of the other variables (including per cent body fat and physical activity), 
except for IL-6, IGFBP-1 and IGFBP-2, which were significantly higher after consumption of the 
olive leaf water extract than after consumption of placebo. 
The Panel considers that this study shows an increase in glucose tolerance without disproportionate 
increase in insulin concentrations after consuming the water extract of fresh olive leaves daily for 12 
weeks under the conditions of use proposed by the applicant. 
The other human intervention study (Komaki et al., 2003) in healthy adult subjects and three animal 
studies (Komaki et al., 2003; Poudyal et al., 2010; Wainstein et al., 2012) assessed the effects of 
powdered olive leaves or of ethanol or hexane/ethanol extracts of olive leaves on blood glucose 
concentrations following acute (Komaki et al., 2003) or chronic (14–16 weeks) consumption (Poudyal 
et al., 2010; Wainstein et al., 2012). The Panel notes that all of these studies were conducted with 
foods which did not comply with the specifications provided by the applicant in relation to the food 
that is the subject of the health claim. The Panel considers that no conclusions can be drawn from 
these studies for the scientific substantiation of the claim. 
With respect to the mechanisms by which the olive leaf water extract could exert the claimed effect, 
the applicant proposed three mechanisms. First, the applicant proposed that an acute increase in IL-6 
in skeletal muscle after exercise could improve insulin-regulated glucose metabolism in the muscle, 
whereas chronically elevated circulating IL-6 concentrations would induce insulin resistance in the 
liver and adipose tissue (Kim et al., 2009). The Panel notes that the human intervention study provided 
(de Bock et al., 2013) assessed differences in circulating IL-6 concentrations in blood samples 
obtained after a 12-hour fast following chronic (12-week) consumption of the olive leaf water extract, 
and thus such increase in IL-6 cannot be considered as “acute” or “localised” in the skeletal muscle. 
The Panel also notes that the role of IL-6 in carbohydrate metabolism is complex and still not well 
understood (Glund et al., 2008). Second, the applicant proposed that the olive leaf water extract 
(oleuropein and tannins) could decrease carbohydrate absorption by inhibiting α-glucosidase in the gut 
or salivary or intestinal α-amylase activity, or could stimulate hepatic glycogen synthesis, which 
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would result in “reduced hyperglycaemia”. However, the study provided in support of that mechanism 
(Wainstein et al., 2012) was not conducted with oleuropein, tannins or the food that is the subject of 
the health claim. Third, the applicant suggested that the olive leaf water extract could exert the claim 
effect by increasing the activity of hepatic antioxidant enzymes via oleuropein and hydroxytyrosol 
(Jemai et al., 2009). The Panel notes that no evidence was provided that “lower activity” of hepatic 
antioxidant enzymes induces glucose intolerance in humans, or that consumption of the olive leaf 
water extract improves glucose tolerance by increasing the activity of hepatic antioxidant enzymes. 
The Panel considers that no evidence was provided by the applicant for a mechanism by which the 
olive leaf water extract could exert the claimed effect in humans. 
In weighing the evidence, the Panel took into account that one human intervention study showed an 
increase in glucose tolerance without a disproportionate increase in insulin concentrations after daily 
consumption of the olive leaf water extract for 12 weeks under the conditions of use proposed by the 
applicant. However, the Panel also took into account that the results have not been replicated in other 
studies, and that the information supplied by the applicant did not provide evidence for a mechanism 
by which the olive leaf water extract could exert the claimed effect. 
The Panel concludes that the scientific evidence is insufficient to establish a cause and effect 
relationship between the consumption of olive leaf water extract and an increase in glucose tolerance. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
• The food, olive leaf (Olea europaea L.) water extract standardised by its content of 
oleuropein, is sufficiently characterised. 
• The claimed effect proposed by the applicant is “reduces the glycaemic response following 
carbohydrate consumption”. The target population proposed by the applicant is adults willing 
to reduce their glycaemic response. Increase in glucose tolerance is a beneficial physiological 
effect as long as serum insulin concentrations are not disproportionately increased. 
• The scientific evidence is insufficient to establish a cause and effect relationship between the 
consumption of olive leaf water extract and increase in glucose tolerance. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on olive leaf water extract and increase in glucose tolerance pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0397_UK). September 2013. 
Submitted by Comvita New Zealand Limited. 
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ABBREVIATIONS 
AUC area under the curve 
BMI body mass index 
CRP C-reacting protein 
DXA dual-energy X-ray absorptiometry 
IGF insulin-like growth factor 
IGFBP insulin-like growth factor growth factor-binding protein 
IL interleukin 
IPAQ International Physical Activity Questionnaire 
ISI insulin sensitivity index 
OGTT oral glucose tolerance test 
OLE olive leaf extract 
SD standard deviation 
TNF tumour necrosis factor 
 
